Janice Wahl Selected Research

uprifosbuvir

12/2017	Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure.
11/2017	Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
11/2017	Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Janice Wahl Research Topics

Disease

30	Infections 05/2018 - 07/2013
12	Chronic Hepatitis C 05/2018 - 07/2013
11	Fibrosis (Cirrhosis) 01/2018 - 08/2014
4	Coinfection 05/2018 - 03/2015
3	Hepatitis C 10/2017 - 01/2016
2	Pneumonia (Pneumonitis) 01/2018 - 01/2017
2	Vomiting 12/2017 - 07/2013
2	Chronic Renal Insufficiency 01/2017 - 10/2015
2	Anemia 02/2016 - 11/2013
1	Opiate Overdose 01/2018
1	Cellulitis 01/2018
1	Chest Pain (Chest Pains) 01/2018
1	Insulin Resistance 01/2018
1	Tachycardia (Tachyarrhythmias) 12/2017
1	Keratitis 11/2017
1	Abscess 11/2017
1	Hemorrhage 01/2017
1	Hemoglobinopathies 01/2017
1	Interstitial Nephritis (Tubulointerstitial Nephritis) 01/2017
1	Pruritus (Itching) 01/2017
1	Virus Diseases (Viral Diseases) 01/2017
1	Hepatocellular Carcinoma (Hepatoma) 03/2015
1	Liver Diseases (Liver Disease) 03/2015
1	Disease Progression 01/2015
1	Dysgeusia (Parageusia) 07/2013
1	Fever (Fevers) 07/2013
1	Hepatitis 07/2013
1	Neutropenia 07/2013
1	Onychomycosis (Tinea Unguium) 09/2011

Drug/Important Bio-Agent (IBA)

25	grazoprevirIBA 05/2018 - 08/2014
21	elbasvirIBA 05/2018 - 03/2015
17	Ribavirin (Virazole)FDA LinkGeneric 01/2018 - 11/2013
8	Antiviral Agents (Antivirals)IBA 01/2018 - 07/2013
8	InterferonsIBA 11/2017 - 03/2015
7	RNA (Ribonucleic Acid)IBA 01/2018 - 07/2013
7	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 02/2016 - 07/2013
6	Protease Inhibitors (Protease Inhibitor)IBA 01/2016 - 07/2013
4	Pharmaceutical PreparationsIBA 11/2017 - 11/2016
3	SofosbuvirIBA 01/2018 - 12/2016
3	ruzasvirIBA 12/2017 - 11/2017
3	uprifosbuvirIBA 12/2017 - 11/2017
3	Proteins (Proteins, Gene)FDA Link 10/2017 - 07/2013
2	Erythropoietin FDA Link 02/2016 - 11/2013
1	SaltsIBA 05/2018
1	CreatinineIBA 01/2018
1	Proton Pump InhibitorsIBA 10/2017
1	Hemoglobins (Hemoglobin)IBA 01/2017
1	Lipase (Acid Lipase)FDA Link 01/2017
1	TabletsIBA 01/2017
1	Opioid Analgesics (Opioids)IBA 11/2016
1	telaprevirIBA 09/2015
1	SimeprevirIBA 09/2015
1	Peptide Hydrolases (Proteases)FDA Link 07/2013
1	posaconazole FDA Link 09/2011

Therapy/Procedure

11	Therapeutics 12/2017 - 11/2013
2	Aftercare (After-Treatment) 01/2018 - 01/2015
2	Duration of Therapy 01/2017 - 03/2015
2	Drug Tapering 02/2016 - 11/2013
1	Retreatment 01/2017